MBRX · Moleculin Biotech, Inc.
$0.61
+0.04 (+7.16%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had an accumulated deficit of $226.5 million since inception and had not yet generated any revenues from operations. Additionally, management anticipates that its cash on hand of $7.3 million as of June 30, 2026, is not sufficient to fund its planned operations for a period of at least one year from when these condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$11.92M
Shares
19.48M
Moleculin Biotech, Inc. Earnings Call Transcripts
Every quarterly earnings call for Moleculin Biotech, Inc. (MBRX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$
−$8.61M
'22 Q3
22-11-10
·
$
−$6.77M
'22 Q4
23-03-23
·
$
−$7.92M
'23 Q1
23-05-11
·
$
−$5.98M
'23 Q2
23-08-11
·
$
−$5.61M
'23 Q3
23-11-13
·
$
−$10.27M
'23 Q4
24-03-22
·
$
−$6.42M
'24 Q1
24-05-13
·
$
−$6.01M
'24 Q2
24-08-14
·
$
−$7.02M
'24 Q3
24-11-12
·
$
−$6.58M
'24 Q4
25-03-24
LATEST
·
$
−$5.90M
'25 Q1
25-05-14
Earnings call
FY25 · Q1
2025-05-14
Moleculin Biotech, Inc. Q1 FY2025 Earnings Call
Confident tone
MIRACLE Phase 3 Trial Progress
Regulatory Approvals and EMA Sign-off
R&D Spend and Manufacturing
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-24
Moleculin Biotech, Inc. Q4 FY2024 Earnings Call
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Moleculin Biotech, Inc. Q3 FY2024 Earnings Call
Confident tone
Annamycin / MIRACLE Phase 3 Trial
Unmet Need in AML
De-risking / Risk Reduction
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Moleculin Biotech, Inc. Q2 FY2024 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Moleculin Biotech, Inc. Q1 FY2024 Earnings Call
Confident tone
First-Line Expansion Opportunity
Regulatory Pathway and End of Phase II Meeting
Combination Therapy Regulatory Risk
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-22
Moleculin Biotech, Inc. Q4 FY2023 Earnings Call
Confident tone
Annamycin AML second-line efficacy
Regulatory pathway and FDA meeting
Lack of cardiotoxicity
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Moleculin Biotech, Inc. Q3 FY2023 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-11
Moleculin Biotech, Inc. Q2 FY2023 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Moleculin Biotech, Inc. Q1 FY2023 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Moleculin Biotech, Inc. Q4 FY2022 Earnings Call
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Moleculin Biotech, Inc. Q3 FY2022 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–11 of 11 earnings calls